Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

REPRESSIT

Financiado

REPRESSIT: A novel class of clinical immune checkpoint inhibitors

In the tumor microenvironment, continuous or tonic stimulation of T cells induces checkpoint signaling through inhibitory immune receptors (IRs). This phenomenon suppresses T cell function, contributing to an exhaustion phenotype... ver más

30/04/2028

NWO-I

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

STICHTING NEDERLANDSE WETENSCHAPPELIJK ONDERZ... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 6 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-13

HORIZON-EIC-2022-PATHFINDEROPEN-01-01: EIC Pathfinder Open 2022 Scope:You should apply to this call if you are looking for support from EIC Pathfinder Open to reali...

I+D

Cerrada hace 2 años

0% 100% 100%

6 Participantes

NWO-I

712.50K€ | Lider

UKB

671.25K€ | Participante

VYCELLIX SWEDEN AB

293.75K€ | Participante

UMC UTRECHT

704.49K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

GPR-ICI Exploration of targeting GPR56 and its cancer cell ligand as... 150K€ Cerrado

RARITY RAtional design of canceR ImmunoTherapY one size does not f... 1M€ Cerrado

PID2020-119567RB-I00 CHARACTERIZATION OF NEW CHECK-POINTS IN CANCER IMMUNOTHERAPY 257K€ Cerrado

INCEPTOR Investigate the mode of action ofInvestigate the mode of act... 192K€ Cerrado

BFU2016-77207-R LAS DIACILGLICEROL QUINASAS COMO NUEVAS DIANAS EN LA INMUNOT... 242K€ Cerrado

SAF2013-48657-R MODULACION DE LA PROGRESION TUMORAL POR ENZIMAS PI3K: APROXI... 484K€ Cerrado

Duración del proyecto: 61 meses Fecha Inicio: 2023-03-13
Fecha Fin: 2028-04-30

Líder del proyecto

STICHTING NEDERLANDSE WETENSCHAPPELIJK ONDERZ... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Descripción del proyecto In the tumor microenvironment, continuous or tonic stimulation of T cells induces checkpoint signaling through inhibitory immune receptors (IRs). This phenomenon suppresses T cell function, contributing to an exhaustion phenotype and their consequent failure to eliminate cancer cells. Checkpoint blockade through IR-targeting antibodies (e.g. anti-PD-1, anti-CTLA-4) can partially reverse this process, and has revolutionized cancer immunotherapy. However, a large fraction of patients, e.g. with tumors that do not express IR ligands, do not benefit from this treatment. Thus, a large unmet need remains to be addressed. We aim to change the current ligand-centric blockade paradigm. The REPRESSIT platform technology developed herein will provide a radically new approach, through development of a novel class of ligand-independent checkpoint therapeutics. These Receptor Inhibition by Phosphatase Recruitment (RIPR) molecules recruit tyrosine phosphatases to the IR and shut down IR signaling, thereby reactivating exhausted T or NK cells to effectively clear cancer cells. The REPRESSIT consortium unites unique complementary expertise and models in IR biology, tumor immunology, protein engineering, biophysics and proteomics, to: 1) define the design principles of RIPR molecules against multiple checkpoint IR targets, 2) evaluate the IR mode of action of signal inhibition, 3) optimize RIPR molecule for their efficacy using preclinical cancer models, and 4) demonstrate in vivo proof-of-concept (PoC)), focusing on a highly-relevant panel of T and NK cell IRs known to display tonic signaling. REPRESSIT will deliver a technology platform for off-the-shelf RIPR designs targeting phosphotyrosine-carrying IR. This project will provide the foundation for our long-term vision of innovative immune checkpoint therapeutics with unprecedented efficacy and provide a greatly improved perspective to the many cancer patients for which current treatment is ineffective.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores